Invention Application
- Patent Title: ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
-
Application No.: US17151006Application Date: 2021-01-15
-
Publication No.: US20210214438A1Publication Date: 2021-07-15
- Inventor: Mark S. Dennis , Zhenyu Gu , Mihalis S. Kariolis , Cathal S. Mahon , Kathryn M. Monroe , Joshua I. Park , Rachel Prorok , Adam P. Silverman , Bettina Van Lengerich
- Applicant: Denali Therapeutics Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Denali Therapeutics Inc.
- Current Assignee: Denali Therapeutics Inc.
- Current Assignee Address: US CA South San Francisco
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
Public/Granted literature
- US11124567B2 Anti-TREM2 antibodies and methods of use thereof Public/Granted day:2021-09-21
Information query
